Your browser doesn't support javascript.
loading
Securing wider EU commitment to the elimination of hepatitis C virus.
Wedemeyer, Heiner; Tergast, Tammo L; Lazarus, Jeffrey V; Razavi, Homie; Bakoyannis, Kostas; Baptista-Leite, Ricardo; Bartoli, Marco; Bruggmann, Philip; Busoi, Cristian-Silviu; Buti, Maria; Carballo, Manuel; Castera, Laurent; Colombo, Massimo; Coutinho, Rodrigo Sousa; Dadon, Yuval; Esmat, Gamal; Esteban, Rafael; Farran, Joan Colom; Gillyon-Powell, Mark; Goldberg, David; Hutchinson, Sharon; Janssen, Harry L A; Kalamitsis, George; Kondili, Loreta A; Lambert, John S; Marinho, Rui Tato; Maticic, Mojca; Patricello, Aldo; Peck-Radosavljevic, Markus; Pol, Stanislas; Poljak, Mario; Pop, Cora; Sokol, Tomislov; Sypsa, Vana; Tözün, Nurdan; Younossi, Zobair; Aghemo, Alessio; Papatheodoridis, George V; Hatzakis, Angelos.
Afiliación
  • Wedemeyer H; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Tergast TL; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Lazarus JV; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Razavi H; Center for Disease Analysis Foundation, Lafayette, Colorado, USA.
  • Bakoyannis K; Mayor of Athens, Mayor's Office, Athens, Greece.
  • Baptista-Leite R; Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
  • Bartoli M; Institute of Health Sciences, Católica University of Portugal, Lisbon, Portugal.
  • Bruggmann P; EpaC Onlus, Monza, Italy.
  • Busoi CS; Arud Centre for Addiction Medicine, Zurich, Switzerland.
  • Buti M; European Parliament, Brussels, Belgium.
  • Carballo M; Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III, Barcelona, Spain.
  • Castera L; International Centre for Migration, Health and Development, Geneva, Switzerland.
  • Colombo M; Department of Hepatology, Hôpital Beaujon AP-HP-University of Paris-VII, Clichy, France.
  • Coutinho RS; Liver Centre, San Raffaele Hospital, Milan, Italy.
  • Dadon Y; Ares do Pinhal, Non-Governmental Organization for Social Inclusion, Lisbon, Portugal.
  • Esmat G; Ministry of Health, Jerusalem, Israel.
  • Esteban R; Endemic Medicine and Department of HepatoGastroenterology Faculty of Medicine, Cairo University Hospital, Cairo, Egypt.
  • Farran JC; Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III, Barcelona, Spain.
  • Gillyon-Powell M; Public Health Agency of Catalonia, Barcelona, Spain.
  • Goldberg D; NHS England and NHS Improvement UK, London, UK.
  • Hutchinson S; Public Health Scotland, Edinburgh, UK.
  • Janssen HLA; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
  • Kalamitsis G; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Kondili LA; Liver Patients' International, Brussels, Belgium.
  • Lambert JS; Istituto Superiore di Sanità, Rome, Italy.
  • Marinho RT; Mater Misericordiae University Hospital, and UCD School of Medicine, Dublin, Ireland.
  • Maticic M; Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal.
  • Patricello A; Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre, Ljubljana, Slovenia.
  • Peck-Radosavljevic M; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Pol S; European Parliament, Brussels, Belgium.
  • Poljak M; Department of Internal Medicine and Gastroenterology (IMuG) Hepatology, Endocrinology, Rheumatology and Nephrology with Centralized Emergency Department (ZAE), Klagenfurt, Austria.
  • Pop C; Department of Hepatology, Université de Paris, APHP, Hopital Cochin, Paris, France.
  • Sokol T; Faculty of Medicine, Institute of Microbiology and Immunology, University of Ljubljana, Ljubljana, Slovenia.
  • Sypsa V; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Tözün N; European Parliament, Brussels, Belgium.
  • Younossi Z; Epidemiology and Preventive Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece.
  • Aghemo A; Department of Gastroenterology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.
  • Papatheodoridis GV; Department of Medicine, Inova Health Fairfax Medical Campus, Fairfax, Virginia, USA.
  • Hatzakis A; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Clinical and Research Hospital, Milan, Italy.
Liver Int ; 43(2): 276-291, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36196744
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programmes-from the municipality level to the EU level-were launched, resulting in an overall decrease in viremic HCV infections and liver-related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID-19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct-acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost-saving than treating and caring for patients with liver-related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale-up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the third EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and reported the 'Call-to-Action' statement supported by all the major relevant European associations in the field.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_covid_19 / 4_hepatitis / 4_pneumonia / 6_digestive_diseases / 6_liver_cancer / 6_other_respiratory_diseases Asunto principal: Hepatitis C / Hepatitis C Crónica / COVID-19 / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_covid_19 / 4_hepatitis / 4_pneumonia / 6_digestive_diseases / 6_liver_cancer / 6_other_respiratory_diseases Asunto principal: Hepatitis C / Hepatitis C Crónica / COVID-19 / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania
...